About this trial

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.

Eligibility criteria

Qualifiers

Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites

Patients with a histologically or cytologically confirmed diagnosis of cancer

Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator

Radiographic imaging (computed tomography [CT], magnetic resonance imaging [MRI], etc.)

Disqualifiers

Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)

Patients with invasive fungal infections

Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection

Actively febrile patients with uncertain etiology of febrile episode

Trial design

Treatments tested in this trial

  • Cytology Specimen Collection Procedure

Treatment groups

5,000 Participants
are divided into 1 treatment group

Locations

140
Alabama
University of Alabama at Birmingham Cancer Center35233, Birmingham United States
Arkansas
Mercy Hospital Fort Smith72903, Fort Smith United States
California
PCR Oncology93420, Arroyo Grande United States
City of Hope Comprehensive Cancer Center91010, Duarte United States

Sponsors and collaborators

National Cancer Institute LAO

Lead sponsor

National Cancer Institute (NCI)

Collaborator